John Militello
Known title: See RemarksCIK: 0001662170
Associated companies
Transaction History
| RCKT | ▼ Sell | Open Market | 384 | $1K | 5/19/2026 | View on chart |
| RCKT | ▼ Sell | Open Market | 855 | $3K | 5/13/2026 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,157 | $4K | 2/18/2026 | View on chart |
| RCKT | ▼ Sell | Open Market | 3,726 | $12K | 2/13/2026 | View on chart |
| RCKT | ▲ Buy | Grant | 29,982 | $0 | 2/11/2026 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,086 | $3K | 11/18/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 19,841 | $79K | 10/14/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 5,514 | $22K | 10/14/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 3,005 | $12K | 10/14/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 558 | $2K | 10/14/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 40,000 | $0 | 9/8/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 361 | $1K | 8/19/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 699 | $2K | 8/18/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 7,043 | $21K | 8/14/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 357 | $2K | 5/20/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 655 | $4K | 5/16/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 718 | $5K | 4/22/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 2,737 | $29K | 2/21/2025 | View on chart |
| RCKT | ▲ Buy | Grant | 20,080 | $0 | 2/11/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 896 | $9K | 1/23/2025 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,224 | $16K | 11/21/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 917 | $15K | 10/31/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,064 | $20K | 8/16/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 812 | $19K | 7/22/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,079 | $25K | 5/16/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 833 | $19K | 4/22/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 2,490 | $70K | 3/21/2024 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 10,000 | $126K | 2/29/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 10,000 | $298K | 2/29/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 3,238 | $97K | 2/16/2024 | View on chart |
| RCKT | ▲ Buy | Grant | 8,322 | $0 | 2/16/2024 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 6,274 | $0 | 2/14/2024 | View on chart |
| RCKT | ▼ Sell | Open Market | 638 | $17K | 1/22/2024 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 1,586 | $0 | 1/18/2024 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 725 | $0 | 11/14/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 564 | $10K | 10/20/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 284 | $4K | 8/17/2023 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 725 | $0 | 8/14/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 573 | $11K | 7/20/2023 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 1,586 | $0 | 7/18/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 245 | $5K | 5/17/2023 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 725 | $0 | 5/14/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 2,342 | $44K | 4/21/2023 | View on chart |
| RCKT | ▲ Buy | Option Exercise | 6,364 | $0 | 4/18/2023 | View on chart |
| RCKT | ▼ Sell | Open Market | 1,244 | $24K | 2/17/2023 | View on chart |
| RCKT | ▼ Sell | Other | 11,067 | $0 | 2/14/2023 | View on chart |
| RCKT | ▼ Sell | Other | 14,310 | $0 | 8/12/2022 | View on chart |
| RCKT | ▼ Sell | Other | 7,932 | $0 | 4/18/2022 | View on chart |
| RCKT | ▼ Sell | Other | 2,903 | $0 | 2/14/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial
Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.
Rocket Pharmaceuticals Gets FDA Alignment on Heart Drug Trial. Rocket Pharmaceuticals has secured FDA alignment on a trial for its heart drug, which may help address prior safety concerns. This regulatory step is significant for the company's development timeline. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite this progress.